News & Perspective

May 11, 2018

May 11, 2018

ASP Scan (Weekly) for May 11, 2018

Rapid diagnostic test for STDs
Free stewardship e-book
Drug maker stewardship program
Med students' antibiotic prescribing
E-learning and prescribing
UK guidance on UTIs
New CARB-X funding
Antibiotic prescribing in primary care

Nov 03, 2017

Nov 03, 2017

ASP Scan (Weekly) for Nov 03, 2017

Livestock-related MRSA
Antimicrobial stewardship recognition
IV antibiotics for UTIs
MRSA vaccine candidate
MCR-1 in pigs
MRSA and patient-sharing
Pneumonia overprescribing
New CARB-X funding
Hospital ASPs
Wales superbug deaths decline
Antibiotics in nursing homes

Mar 14, 2017

Mar 14, 2017

Stewardship / Resistance Scan for Mar 14, 2017

Antibiotic misconceptions
Sexual spread of resistant bacteria
New gram-negative antibiotic

Jun 28, 2016

Jun 28, 2016

News Scan for Jun 28, 2016

Saudi MERS cases
2009 H1N1 origins in Mexico
WHO health emergency head
Strategic National Stockpile report

Oct 27, 2014

Oct 27, 2014

CSL-Novartis deal includes US cell-based flu vaccine plant

The $275 million deal will make the company the second leading player in the $4 billion global flu vaccine market.

Feb 14, 2013

Feb 14, 2013

Euro studies show flu vaccine working best against type B

(CIDRAP News) – New European studies reported today in Eurosurveillance suggest that this year's influenza vaccine is providing good protection against influenza B viruses but only moderate protection against type A—findings more or less consistent with earlier results in the United States.

May 18, 2011

May 18, 2011

Experts: Regulatory issues are main reason for keeping smallpox virus

(CIDRAP News) – When the World Health Assembly (WHA) considers the fate of the remaining stocks of smallpox virus this week, the debate is likely to be framed in part by a report from a group of independent experts that says the only strong reason for keeping the virus is to satisfy strict regulatory requirements for new vaccines and antivirals.

Feb 11, 2011

Feb 11, 2011

Study showing high effectiveness for H1N1 vaccine stirs debate

(CIDRAP News) – A recent case-control study estimates that the adjuvanted pandemic H1N1 influenza vaccine used in Canada was effective 93% of the time, a substantially higher figure than seen in several other studies and one that has raised some eyebrows among other flu vaccine researchers.

Pages

Sort Results By:

 Sort Results By:

Narrow results by:

by country

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation 3MAccelerate DiagnosticsGilead 
Grant support for ASP provided by

  Become an underwriter»